The ongoing Phase II clinical trial investigates the combination of relatlimab (Anti-LAG3), nivolumab (Anti-PD1), and 5-azacytidine in patients with refractory/relapsed Acute Myeloid Leukemia (AML) and newly diagnosed older AML patients. Given the high unmet medical need in AML, particularly among older patients who are often unfit for intensive therapies, successful outcomes could position this combination therapy as a novel treatment option in a competitive landscape dominated by traditional chemotherapeutics and emerging immunotherapies. The trial's focus on safety and tolerability, alongside efficacy measures like objective response rate (ORR), will be critical for future regulatory submissions and market access strategies. The study is being conducted by Ludwig-Maximilians University of Munich, which may enhance credibility and attract potential partnerships or investments.